Pharmaceutics 2010, 2(3), 313-320; doi:10.3390/pharmaceutics2030313
Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease
Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
*
Author to whom correspondence should be addressed.
Received: 1 June 2010 / Revised: 26 August 2010 / Accepted: 14 September 2010 / Published: 20 September 2010
Abstract
Application of oral fast release amantadine and levodopa may induce an improvement of motor symptoms in patients with Parkinson’s disease (PD). The objective of this trial was to investigate the clinical efficacy of a fast release amantadine sulfate formulation on simple and complex movement performance and putative relations to the pharmacokinetic behavior in PD patients. We challenged two cohorts of 12 PD patients, who were taken off their regular antiparkinsonian treatment for at least 12 hours, with oral 300 mg amantadine sulfate. We scored motor symptoms and performed instrumental tasks, which ask for performance of simple or complex motion series under cued conditions. Motor symptoms and performance of complex movements significantly improved in contrast to the carrying-out of simple motions. N-methyl-D-aspartic acid antagonistic and dopaminomimetic amantadine also influences altered higher predominant prefrontal cognitive functions. Therefore, performance of complex motion series improved, whereas carrying-out of simple repetitive movements is more associated to the striatal dopamine dependent basal ganglia function.Keywords:
Parkinson’s disease; amantadine; motion; cognition
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Scifeed alert for new publications
Never miss any articles matching your research from any publisher- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Share & Cite This Article
MDPI and ACS Style
Muhlack, S.; Müsch, P.; Konietzka, S.; Woitalla, D.; Przuntek, H.; Müller, T. Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease. Pharmaceutics 2010, 2, 313-320.
Related Articles
Article Metrics
Comments
[Return to top]
Pharmaceutics
EISSN 1999-4923
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert